[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,803,752
  • Shares Outstanding, K 62,818
  • Annual Sales, $ 4,268 M
  • Annual Income, $ -356,150 K
  • EBIT $ 462 M
  • EBITDA $ 1,159 M
  • 60-Month Beta 0.32
  • Price/Sales 3.72
  • Price/Cash Flow 15.55
  • Price/Book 3.50

Options Overview Details

View History
  • Implied Volatility 41.60% (-3.23%)
  • Historical Volatility 27.50%
  • IV Percentile 86%
  • IV Rank 36.07%
  • IV High 69.53% on 08/05/25
  • IV Low 25.84% on 11/24/25
  • Expected Move (DTE 16) 15.47 (5.91%)
  • Put/Call Vol Ratio 0.55
  • Today's Volume 424
  • Volume Avg (30-Day) 182
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 6,449
  • Open Int (30-Day) 5,175
  • Expected Range 246.15 to 277.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $5.38
  • Number of Estimates 5
  • High Estimate $5.63
  • Low Estimate $5.03
  • Prior Year $6.99
  • Growth Rate Est. (year over year) -23.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
233.46 +12.06%
on 07/15/26
262.00 -0.15%
on 08/04/26
+18.15 (+7.45%)
since 07/02/26
3-Month
208.41 +25.53%
on 05/05/26
262.00 -0.15%
on 08/04/26
+53.56 (+25.74%)
since 05/04/26
52-Week
105.00 +149.16%
on 08/06/25
262.00 -0.15%
on 08/04/26
+145.52 (+125.34%)
since 08/04/25

Most Recent Stories

More News
Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales

Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales

JAZZ : 261.62 (+3.99%)
Jazz: Q2 Earnings Snapshot

Jazz: Q2 Earnings Snapshot

JAZZ : 261.62 (+3.99%)
Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

– Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) –

JAZZ : 261.62 (+3.99%)
Jazz Pharmaceuticals (JAZZ) Q2 Earnings: What To Expect

Jazz Pharmaceuticals (JAZZ) Q2 Earnings: What To Expect

JAZZ : 261.62 (+3.99%)
Jazz Pharmaceuticals' Rare Oncology Momentum May Already Be Priced Into Next Week's Print

Barchart Research What to Expect from JAZZ Earnings JAZZ Generated July 31, 2026 Current Price $252.86 EPS Estimate $$5.06 Consensus Rating Strong Buy Average Move 6.51% Jazz Pharmaceuticals' Rare Oncology...

JAZZ : 261.62 (+3.99%)
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026

DUBLIN , July 20, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close...

JAZZ : 261.62 (+3.99%)
Stocks Finish Sharply Lower as Tech Stocks Slump

The S&P 500 Index ($SPX ) (SPY ) on Friday closed down -1.01%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.77%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.49%. September...

AMAT : 546.62 (+5.48%)
GOOGL : 377.65 (+1.11%)
MPC : 312.61 (+1.82%)
AAPL : 309.38 (+1.96%)
SNDK : 1,427.62 (+10.84%)
CVX : 190.40 (-1.44%)
ROAD : 106.71 (-1.30%)
TXN : 283.63 (+5.42%)
ALV : 124.58 (+0.65%)
$IUXX : 29,733.16 (+3.32%)
ASML : 1,711.89 (+4.22%)
ZNU26 : 108-295 (+0.07%)
Stocks Pressured by Global Slide in Chipmakers

The S&P 500 Index ($SPX ) (SPY ) today is down -0.87%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.76%. September E-mini S&P futures...

MSTR : 97.65 (+2.94%)
GOOGL : 377.65 (+1.11%)
AAPL : 309.38 (+1.96%)
ADI : 380.29 (+5.09%)
ROAD : 106.71 (-1.30%)
GLXY : 22.14 (+1.19%)
ALV : 124.58 (+0.65%)
COIN : 150.73 (+2.89%)
TSLA : 327.35 (+1.64%)
JAZZ : 261.62 (+3.99%)
WDC : 548.56 (+4.05%)
AMD : 518.58 (+7.00%)
Stocks Tumble as the Rout in Chipmakers Deepens

The S&P 500 Index ($SPX ) (SPY ) today is down -1.06%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.23%. September E-mini S&P futures...

MSTR : 97.65 (+2.94%)
GOOGL : 377.65 (+1.11%)
AAPL : 309.38 (+1.96%)
SNDK : 1,427.62 (+10.84%)
HL : 15.39 (+6.65%)
CDE : 16.21 (+4.18%)
ROAD : 106.71 (-1.30%)
GLXY : 22.14 (+1.19%)
ALV : 124.58 (+0.65%)
COIN : 150.73 (+2.89%)
TSLA : 327.35 (+1.64%)
JAZZ : 261.62 (+3.99%)
3 Value Stocks with Open Questions

3 Value Stocks with Open Questions

CHDN : 85.35 (+2.25%)
JAZZ : 261.62 (+3.99%)
HCAT : 2.28 (+3.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients....

See More

Key Turning Points

3rd Resistance Point 281.19
2nd Resistance Point 271.59
1st Resistance Point 266.61
Last Price 261.62
1st Support Level 252.03
2nd Support Level 242.43
3rd Support Level 237.45

See More

52-Week High 262.00
Last Price 261.62
Fibonacci 61.8% 202.03
Fibonacci 50% 183.50
Fibonacci 38.2% 164.97
52-Week Low 105.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.